Tag: 50998-17-9

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,50998-17-9

In toluene (8 mL) was placed 1- (diphenylmethylene)hydrazine (1.00 g, 5.10 mmol), palladium acetate (10.4 mg, 0.0464 mmol) and 2-(diphenylphosphino)- 1 -(2-(diphenylphosphino)naphthalen- 1 -yl)naphthalene (44 mg, 0.0696 mmol) and the reaction was stirred at 100 C under Ar for 5 min and then cooled to RT. To this dark purple solution was added 6-bromoquinoxaline (970 mg, 4.64 mmol), sodium t-butoxide (624 mg, 6.50 mmol) and toluene (2 mL). The reaction was placed under Ar and warmed to 100 C for 5 hrs, cooled to RT and stirred overnight. The reaction was diluted with ether (50 mL) and water (30 mL) and filtered through a Celite pad. The pad was washed with ether (20 mL) and water (20 mL). The combined organic layers were washed with brine (50 mL), dried (Na2SC>4), concentrated in vacuo and purified by chromatography (ethyl acetate/hexanes) to give l-(diphenylmethylene)-2- (quinoxalin-6-yl)hydrazine (305 mg, 20% yield) as a bright yellow foam. FontWeight=”Bold” FontSize=”10″ H NMR (300 MHz, DMSO-i/e) delta 7.35-7.41 (m, 5 H), 7.51-7.53 (m, 2 H), 7.58-7.65 (m, 3 H), 7.75 (s, 1 H), 7.89 (s, 2 H), 8.61 (s, 1 H), 8.74 (s, 1 H), 9.60 (s, 1 H); MS (ESI) m/z: 325.0 (M+H+).

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; DECIPHERA PHARMACEUTICALS, LLC; FLYNN, Daniel L.; PETILLO, Peter A.; KAUFMAN, Michael D.; WO2013/36232; (2013); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

EXAMPLE 1276-[3-(lH-Pyrazol-l-yl)phenyl]quinoxaline6-Bromoquinoxaline (100 mg, 0.48 mmol), 3-(lH-pyrazol-l-yl)phenylboronic acid (108 mg, 0.57 mmol), Na2CO3 (0.15 g, 1.44 mmol), Pd(PPh3)4 (55 mg, 0.048 mmol), water (2 mL) and DME (6 mL) were combined in a sealed tube and heated under microwave irradiation to 12O0C for 1 h. The reaction mixture was concentrated to dryness and purified by preparative EtaPLC to give the title compound (62.1 mg, 47%) as a pale yellow solid. deltaEta (CDCl3) 8.89 (IH, d, J 1.84 Hz), 8.86 (IH, d, J 1.84 Hz), 8.38 (IH, d, J2.05 Hz), 8.20 (IH, d, J8.74 Hz), 8.15-8.09 (2H, m), 8.03 (IH, d, J2.51 Hz), 7.78 (IH, d, J 1.76 Hz), 7.75 (IH, ddd, J8.00, 2.25, 1.14 Hz), 7.69-7.66 (IH, m), 7.63-7.55 (IH, m), 6.52 (IH, dd, J2.50, 1.78 Hz). LCMS (ES+) 273 (M+H)+, 15.14 minutes {Method 4).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

To a stirred solution of 6-bromoquinoxaline (1.0 g, 4.78 mmol) in DMF (10 ml) and water (0.5 ml)was added zinc cyanide (1.404 g, 11.96 mrnol), Pd2(dba)3 (0.219 g. 0.239 mmol) and 2-dicvclohexylphosphino-2,4,6-tri-iso-propyl-1,i-hiphenyl (0.114 g, 0.239 mmol) in microvve vial. The reaction mixture was degassed under nitrogen and heated in microwave at 150 C for ili. The reaction mixture was diluted with water and extracted with ethyl acetate (2 x 150 ml). A combined organic layer was evaporated under reduced pressure. The crude product was purified by columnchromatography on silica gel using Ethyl acetate/1-Iexane as an eluent to afford quinoxaline-6- carbonitrile (0.250 g, 33.7%) as a solid.

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various.

Reference£º
Patent; PI INDUSTRIES LTD.; SAXENA, Rohit; PANMAND, Deepak Shankar; JENA, Lalit Kumar; SRIVASTAVA, Khushboo; RAJU, Jella Rama; MANJUNATHA, Sulur G; SAMANTA, Jatin; GARG, Ruchi; AUTKAR, Santosh Shridhar; VENKATESHA, Hagalavadi M; GADAKH, Ramdas Balu; KLAUSENER, Alexander G. M.; POSCHARNY, Konstantin; (219 pag.)WO2018/116072; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of 8-(4-chlorophenyl)-2-((2,2,2- trifluoroethyl)amino)pyrido[4,3-i/]pyrimi-din-7(d7/)-one (100 mg, 0.28 mmol, 1.0 equiv), 5-bromo-2-methyl-2H-indazole (119 mg, 0.56 mmol, 2.0 equiv.), Cul (5.4 mg, 0.028 mmol, 0.1 equiv.), N1, A2-dimethylcy cl ohexane-l, 2-diamine (8.1 mg, 0.056 mmol, 0.2 equiv.), CS2CO3 (276 mg, 0.847 mmol, 3.0 equiv.) and dioxane (2 mL) was stirred at l00C under N2 atmosphere for l6h. The crude mixture was concentrated under reduced pressure, and the resulting residue was purified by flash column chromatography on silica gel to yield 8-(4- chlorophenyl)-6-(2-methyl-2H-indazol-5-yl)-2-((2,2,2- tri fl uoroethyl )am i no)py ri do[-/, 3-6/]pyrimidin-7(6//)-one (Example 123).

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; AGIOS PHARMACEUTICALS, INC.; KONTEATIS, Zenon D.; LI, Mingzong; LIU, Peng; MEDEIROS, Matthew; REZNIK, Samuel K.; SUI, Zhihua; TRAVINS, Jeremy M.; POPOVICI-MULLER, Janeta; ZHOU, Shubao; MA, Guangning; (298 pag.)WO2019/191470; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The A8-1 (63mg, 0.30mmol) was dissolved in dioxane (6mL), bis (pinacolato) borate (91mg, 0.36mmol), KOAc (59mg,0.60mmol), Pd (dppf) 2Cl2 (25mg, 0.03mmol), purged with nitrogen, 90 stirred for 2 hours, cooled to room temperature, suction filtered through Celite, the filterLiquid spin dry to give crude black oil (160mg), was used directly in the next step.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Suzhou Yunxuan Pharmaceutical Co., Ltd.; Zhang, Xiaohu; (54 pag.)CN105254613; (2016); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6-Bromoquinoxaline (4.61 g) and tert-butyl 5-hydroxy-4-methyl-2,3-dihydro-1H-indole-1-carboxylate (5.00 g) 1,4-dioxane (15 mL) solution of copper iodide (I) (0.763 g), N,N-dimethylglycine (0.827 g) and cesium carbonate (13.1 g) was added, and stirred for 25 hours at 90 C. After cooling, the ethyl acetate was added to the reaction mixture, and the insoluble material was removed by filtration. The solvent was distilled off under reduced pressure, the residue was purified by column chromatography (ethyl acetate / hexanes ? methanol /dichloromethane) to give a mixture containing the title compound (0.370 g).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DAIICHI SANKYO COMPANY LIMITED; NAGAMOCHI, MASATOSHI; GOTANDA, KENTOKU; NOGUCHI, TETSUJI; GOTO, TAIJI; SASAKI, JUNKO; TORIHATA, MUNEFUMI; YOSHINO, TOSHIHARU; ISOBE, TAKASHI; (97 pag.)JP2016/108257; (2016); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

Under nitrogen, [Rh(COD)Cl]2, Zn powder, KOH and 1.0 mL of toluene were added to a Schlenk tube equipped with a magnetic stir bar. A toluene solution of 6-bromoquinoxaline (1.0 mL) was added to the above mixture. After adding H2O, the mixture was stirred at 70 C. Monitor by TLC until 6-bromoquinoxaline is completely consumed. Of which 6-bromoquinoxaline, [Rh(COD)Cl]2, Zn powder, The molar ratio of KOH to H2O is 1: 0.025: 3: 0.4: 20. The residue was purified by silica gel column chromatography, the desired product 6-bromo-1,2,3,4-tetrahydroquinoxaline was obtained. White solid, yield 38%,

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Yunnan Nationalities University; Chen Jingchao; Zhou Yongyun; Fan Baomin; Sun Weiqing; Fan Ruifeng; Zeng Guangzhi; Zhang Xia; (13 pag.)CN110483420; (2019); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 11j (30 mg, 120 mumol), 6-bromoquinoxaline (37.6 mg, 180 mumol), Bu4NOAc (72.2 mg, 23.9 mumol) and Pd(OAc)2 (4.0 mg, 17.8 mol) in NMP (0.5 mL ). The reaction mixture was stirred for 11 h at 100 oC and cooled to room temperature. The mixture was concentrated under reduced pressure. Diluted with water and extracted with EtOAc (3 ¡Á 5 mL). The EtOAc solution was washed with brine (5 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford the compound 12j (15.8 mg, 35%) as a pale yellow solid. TLC: Rf 0.41 (1:1 hexane/EtOAc). mp: 188190 oC. 1H-NMR (400 MHz, CDCl3) delta 8.89 (d, 1H, J = 1.6 Hz), 8.85 (d, 1H, J = 1.6 Hz), 8.11 (d, 1H, J = 8.8 Hz), 8.07 (d, 1H, J = 1.6 Hz), 7.76 (dd, 1H, J = 8.8 Hz, J = 1.6 Hz), 7.73 (t, 1H, J = 8.0 Hz), 7.63 (d, 1H, J = 8.0 Hz), 7.47 (d, 2H, J = 8.0 Hz), 7.13-7.08 (m, 3H), 2.32 (s, 3H), 2.19 (s, 3H). 13C-NMR (100 MHz, CDCl3) delta 158.3, 149.2, 146.3, 145.9, 145.8, 143.0, 142.8, 139.1, 138.4, 132.7, 132.1, 131.6, 131.2, 129.5, 128.8, 127.8, 127.5, 123.7, 115.7, 23.8, 21.4. HRMS (ESI) calcd. for C23H19N6 (M+H): 379.1666; found 379.1671

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Article; Li, Fei; Park, Yunjeong; Hah, Jung-Mi; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry Letters; vol. 23; 4; (2013); p. 1083 – 1086;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 6-bromoquinoxaline (0.40 g, 1.9 mmol), 2-propen-l-ol (0.260 mL, 3.8 mmol), tris(dibenzylideneacetone)dipalladium (26 mg, 0.029 mmol), tri-tert-butylphosphonium tetrafluoroborate (16 mg, 0.057 mmol) and N-cyclohexyl-N-methyl-cyclohexanamine (0.49 mL, 2.3 mmol) in 1,4-dioxane (3.0 mL) was stirred at 40 0C overnight. After cooling to RT, the mixture was filtered, washed with methylene chloride and the filtrate was concentrated. The crude material was purified by chromatography on silica gel with EtOAc in Hexane (0-40%) to afford the desired product (195 mg). LCMS: (M+H) = 187.3.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; INCYTE CORPORATION; ZHUO, Jincong; METCALF, Brian; WO2008/64157; (2008); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

Example 60. 6-Quinoxaline boronic acid, pinacol ester (S50)To 6-bromoquinoxaline (418 mg, 2.00 mmol, 1.00 equiv) in dioxane (10 niL) at 23 0C was added PdCl2(dppf) -CH2Cl2 (163 mg, 0.200 mmol, 0.100 equiv), bis(pinacolato)diborone (610 mg, 2.40 mmol, 1.20 equiv), and KOAc (392 mg, 4.00 mmol, 2.00 equiv). After stirring for 1.5 hr at 900C, the reaction mixture was cooled to 23 0C and concentrated in vacuo. The residue was dissolved in CH2Cl2 and filtered through a plug of Celite. After the removal of CH2Cl2, the residue was purified by chromatography on silica gel eluting with hexanes/EtOAc 4:1 (v/v) to afford 500 mg of the title compound as a colorless solid (98% yield).R/= 0.45 (hexanes/EtOAc 1:1 (v/v)). NMR Spectroscopy: 1H NMR (500 MHz, CDCl3, 23 0C, delta): 8.86-8.82 (m, 2H), 8.59 (s, IH), 8.12 (dd, /= 8.0 Hz, 2.0 Hz, IH), 8.06 (d, / = 8.0 Hz, IH), 1.37 (s, 12H). 13C NMR (125 MHz, CDCl3, 23 0C, delta): 145.53, 145.03, 144.37, 142.41, 137.31, 134.75, 131.90 (br), 128.44, 84.36, 24.86. Mass Spectrometry: HRMS-FIA (m/z): Calcd for [M + H]+, 257.14558. Found, 257.14440.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; RITTER, Tobias; FURUYA, Takeru; TANG, Pingping; WO2010/59943; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider